How Can the SGR be Fixed

Oncology leaders say clinical pathways must shift from static documents to tools that use patient-reported outcomes and AI to guide care.

SCOUT-HCM 56-week data show sustained LVOT gradient reductions with mavacamten and no LVEF below 50% in adolescents with obstructive HCM.

New analyses from VESALIUS-CV and the FOURIER open-label extension add stroke and long-term outcome data for evolocumab.

First-line IVF produced more live births than IUI within 7 months in couples with unexplained infertility.

Elafibranor and seladelpar normalized ALP in most patients with primary biliary cholangitis whose ALP was below the usual escalation threshold.

The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.

Most patients with MASH stay on resmetirom at 1 year, but Medicaid coverage was tied to lower odds of filling a first prescription within 30 days.

A 20-year review traces how immune checkpoint inhibitors became a cornerstone of lung cancer treatment.